RecruitingPhase 1Phase 2NCT05599048

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

A Phase I/II Study of Hyperpolarized 13C MRI as a Biomarker of Aggressiveness & Response to Therapy in Patients With Advanced Solid Tumors

Sponsor

Robert Bok, MD, PhD

Enrollment

65 participants

Start Date

Dec 15, 2022

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor

Summary

This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 13C,15N-Urea, a drug called Hyperpolarized 13C-Pyruvate, and others for people with advanced solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.